WOMEN IN PHARMA LIMITED

Executive Summary

Women In Pharma Limited, a newly incorporated micro private limited company, currently shows negative net assets and long-term liabilities exceeding its assets, indicating a high solvency risk. The short-term liquidity position appears stable, and statutory filings are compliant, but limited operational scale and financial history introduce uncertainty. Further due diligence on creditor terms and cash flow projections is recommended to fully assess financial sustainability.

WOMEN IN PHARMA LIMITED - Analysis Report

Company Number: 14527328

Analysis Date: 2025-07-29 14:03 UTC

1. Risk Rating: HIGH
   The company’s latest filed accounts show net liabilities of £1,114, indicating negative net assets. Moreover, the balance sheet presents a mismatch between current assets and creditors falling due after more than one year, suggesting long-term liabilities exceeding total assets. This points to solvency concerns. The company is also very new, incorporated in late 2022, with limited financial history, which increases uncertainty.

2. Key Concerns:

• Negative Net Assets: Total net assets are reported as negative (£-1,114), implying the company’s liabilities exceed its assets, which raises solvency risk.
• Long-Term Creditors Exceed Assets: Creditors due after more than one year (£5,153) are higher than total assets less current liabilities (£4,039), suggesting potential difficulties meeting long-term obligations.
• Limited Financial History and Scale: As a micro-entity with only 2 employees and minimal fixed assets, operational stability and cash flow capacity to cover liabilities is uncertain.

3. Positive Indicators:

• Current Assets Above Current Liabilities: Current assets (£3,939) exceed current liabilities, providing some short-term liquidity cushion.
• No Overdue Filings: Accounts and confirmation statements are up to date, indicating compliance with statutory filing requirements.
• Ownership and Control Transparency: The two directors each hold 25-50% share and voting rights with equal control, which may support governance clarity.

4. Due Diligence Notes:

• Investigate the nature and terms of the long-term creditors to assess repayment schedules and risks.
• Review cash flow statements and management forecasts to evaluate liquidity beyond the balance sheet snapshot.
• Understand the business model and revenue generation plans given the micro scale and recent incorporation.
• Confirm absence of director disqualifications or regulatory issues through official records.
• Verify the accuracy of reported figures and confirm whether any off-balance sheet obligations exist.